← Back to Search

VGT-309 for Lung Cancer

Phase 2

Waitlist Available

Research Sponsored by Vergent Bioscience, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up during surgery

Awards & highlights

Study Summary

This trial is testing a new way to find cancer in people who are having surgery for lung cancer.

Eligible Conditions

Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ during surgery

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~during surgery

This trial's timeline: 3 weeks for screening, Varies for treatment, and during surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The proportion of subjects with at least one Clinically Significant Event (CSE)

Secondary outcome measures

Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value of VGT-309

Trial Design

1Treatment groups

Experimental Treatment

Group I: 0.32mg/kg VGT-309Experimental Treatment1 Intervention

Single arm in an open label study

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

VGT-309

2022

Completed Phase 2

~40

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Vergent Bioscience, Inc.Lead Sponsor

1 Previous Clinical Trials

100 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,657 Previous Clinical Trials

40,933,627 Total Patients Enrolled

Curt Scribner, MDStudy DirectorVergent Bioscience

1 Previous Clinical Trials

2 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experimental procedure have an age limit?

"If patients meet the age requirements of 18 or older, and are no more than 85 years old, they are eligible to participate in this clinical trial."

Answered by AI

Could you tell me if there are any available positions for patients in this trial?

"That is correct, the online information indicates that the clinical trial is still recruiting patients. This study was originally shared on May 24th, 2022 and was updated as recently as October 4th, 2022. Currently, the plan is to enroll 40 people total from 1 location."

Answered by AI

How does VGT-309 compare to other treatments in terms of risk?

"While there is some evidence that VGT-309 is safe, as this is a Phase 2 trial, it has not yet been proven effective. Therefore, it receives a safety score of 2."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase 2 Study of VGT-309 in Lung Cancer

2022. "Phase 2 Study of VGT-309 in Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05400226.